Mathew Alan Carrigan

Title: Innovator Mathew Alan Carrigan and His Contribution to Mitochondrial Research

Introduction

Mathew Alan Carrigan is an accomplished inventor based in Dublin, Ireland. With a focus on biotechnology and genetics, he holds a significant patent that addresses mitochondrial dysfunction, showcasing his dedication to advancing medical science through innovative research.

Latest Patents

Carrigan’s notable patent is titled "Variants of yeast NDI1 gene, and uses thereof in the treatment of disease associated with mitochondrial dysfunction." This invention involves an isolated nucleic acid sequence that encodes the yeast NDI1 protein or its functional variants. The nucleic acid sequence is optimized to include at least 50 codons, providing a substantial improvement over the original yeast NDI1 gene sequence. This patent represents a crucial step toward developing therapeutic options for diseases linked to mitochondrial dysfunction.

Career Highlights

Carrigan is currently affiliated with the Provost Fellows Foundation Scholars and the Board of the College of the Holy and Undivided Trinity of Queen Elizabeth, located at Trinity College Dublin. His work in this prestigious institution allows him to engage in groundbreaking research and contribute to advancements in genetic therapies.

Collaborations

Throughout his career, Mathew has collaborated with talented colleagues, including Gwyneth Jane Farrar and Sophia Millington-Ward. Their collective expertise nurtures an environment ripe for innovation, ultimately improving outcomes in biomedical applications.

Conclusion

Mathew Alan Carrigan exemplifies how focused innovation can lead to significant advancements in the treatment of complex diseases. With his patent on the yeast NDI1 gene variants, he is poised to make a lasting impact in the field of mitochondrial research, offering hope for many individuals affected by mitochondrial dysfunction.